These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19364250)

  • 21. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E; Ceravolo R; Bonuccelli U
    Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of apomorphine in the treatment of Parkinson's disease.
    Boyle A; Ondo W
    CNS Drugs; 2015 Feb; 29(2):83-9. PubMed ID: 25676564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease.
    Kolls BJ; Stacy M
    Clin Neuropharmacol; 2006; 29(5):292-301. PubMed ID: 16960475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.
    Antonini A; Odin P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S97-100. PubMed ID: 20123567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
    Hauser RA; Isaacson S; Clinch T;
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.
    Hughes AJ; Webster R; Bovingdon M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1991 Dec; 14(6):556-61. PubMed ID: 1773424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
    Henriksen T
    Neurodegener Dis Manag; 2014; 4(3):271-82. PubMed ID: 25095821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.